Sozen T, Ozisik L, Basaran NC (2017) An overview and management of osteoporosis (in eng). Eur J Rheumatol 4:46–56. https://doi.org/10.5152/eurjrheum.2016.048

Article  PubMed  Google Scholar 

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures (in eng). Osteoporos Int 17:1726–1733. https://doi.org/10.1007/s00198-006-0172-4

Article  CAS  PubMed  Google Scholar 

Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis (in Eng). J Clin Endocrinol Metab 104:1623–1630. https://doi.org/10.1210/jc.2019-00192

Article  PubMed  Google Scholar 

Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact (in Eng). Arch Intern Med 151:2026–2032

Article  CAS  PubMed  Google Scholar 

Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis (in Eng). Bone 18:185S-S189. https://doi.org/10.1016/8756-3282(95)00500-5

Article  CAS  PubMed  Google Scholar 

Visschedijk J, van Balen R, Hertogh C, Achterberg W (2013) Fear of falling in patients with hip fractures: prevalence and related psychological factors (in Eng). J Am Med Dir Assoc 14:218–220. https://doi.org/10.1016/j.jamda.2012.10.013

Article  PubMed  Google Scholar 

Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States (in Eng). Mayo Clin Proc 90:53–62. https://doi.org/10.1016/j.mayocp.2014.09.011

Article  PubMed  Google Scholar 

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures (in Eng). Osteoporos Int 11:556–561. https://doi.org/10.1007/s001980070075

Article  CAS  PubMed  Google Scholar 

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group (1994) (in Eng). World Health Organization technical report series 843:1–129

Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis (in Eng). J Bone Miner Res 18:18–23. https://doi.org/10.1359/jbmr.2003.18.1.18

Article  CAS  PubMed  Google Scholar 

Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K et al (2011) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP) (in Eng). J Bone Miner Metab 29:37–43. https://doi.org/10.1007/s00774-010-0188-x

Article  CAS  PubMed  Google Scholar 

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures (in Eng). J Clin Endocrinol Metab 90:1583–1587. https://doi.org/10.1210/jc.2004-0826

Article  CAS  PubMed  Google Scholar 

Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women (in Eng). Osteoporos Int 30:3–44. https://doi.org/10.1007/s00198-018-4704-5

Article  CAS  PubMed  Google Scholar 

Lippuner K (2012) The future of osteoporosis treatment - a research update (in Eng). Swiss Med Wkly 142:w13624. https://doi.org/10.4414/smw.2012.13624

Article  PubMed  Google Scholar 

Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate (in Eng). J Bone Miner Res 19:745–751. https://doi.org/10.1359/JBMR.040117

Article  CAS  PubMed  Google Scholar 

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial (in Eng). Lancet 386:1147–1155. https://doi.org/10.1016/S0140-6736(15)61120-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent (in Eng). J Clin Endocrinol Metab 94:3772–3780. https://doi.org/10.1210/jc.2008-2719

Article  CAS  PubMed  Google Scholar 

McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A (2018) Effects of 24 Months of treatment with romosozumab followed by 12 Months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, Double-Blind, Phase 2, Parallel Group Study (in Eng). J Bone Miner Res 33:1397–1406. https://doi.org/10.1002/jbmr.3452

Article  CAS  PubMed  Google Scholar 

McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab (in Eng). Osteopor Int 31:2231–2241. https://doi.org/10.1007/s00198-020-05502-0

Article  CAS  Google Scholar 

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis (in Eng). N Engl J Med 375:1532–1543. https://doi.org/10.1056/NEJMoa1607948

Article  CAS  PubMed  Google Scholar 

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis (in Eng). N Engl J Med 377:1417–1427. https://doi.org/10.1056/NEJMoa1708322

Article  CAS  PubMed  Google Scholar 

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (in Eng). Lancet 390:1585–1594. https://doi.org/10.1016/S0140-6736(17)31613-6

Article  CAS  PubMed  Google Scholar 

Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H (2016) Bisphosphonate pre-treatment diminishes the therapeutic benefits of teriparatide in japanese osteoporotic patients (in Eng). Tohoku J Exp Med 239:17–24. https://doi.org/10.1620/tjem.239.17

Article  CAS  PubMed  Google Scholar 

Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and current options for postmenopausal osteoporosis (in Eng). Expert Opin Pharmacother 17:1141–1152. https://doi.org/10.1080/14656566.2016.1176147

Article  CAS  PubMed  Google Scholar 

Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Hirao M, Okamura G, Etani Y, Takami K, Goshima A, Miura T, Nakata K, Okada S (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis (in Eng). Joint Bone Spine 88:105219. https://doi.org/10.1016/j.jbspin.2021.105219

Article  CAS  PubMed  Google Scholar 

Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J, Nakamura Y (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study (in Eng). Bone Rep 14:101068. https://doi.org/10.1016/j.bonr.2021.101068

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study (in Eng). Osteoporos Int 32:1999–2009. https://doi.org/10.1007/s00198-021-05925-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miya